In an independent, ethics-approved, double blind, randomized, placebo controlled clinical trial conducted by Gupte PA et al, Longvida Optimized Curcumin was evaluated for safety and efficacy against ibuprofen (males and females aged 40-65 yrs). The study, published in the Journal of Inflammation Research, found Longvida, at a daily dose of 800mg, was safe and effective when administered for 90 days.

Forty-two subjects (n=25 ibuprofen, n=17 Longvida), exhibited significant improvements in VAS and WOMAC scores compared to baseline. Findings concluded Solid Lipid Curcumin Particle (SLCP ) Longvida was not only safe and effective, but also found Longvida to provide “faster acting pain relief” compared to ibuprofen in the first 30 days. Additionally, no significant changes in blood or urine parameters were reported, nor were any serious adverse side effects reported during the study period, further confirming the safety of Longvida Optimized Curcumin.1

Joint PainThe promising results from this study further confirm the safety and efficacy of Longvida. Not only is it exciting to see the results from this study, but further establishes Longvida’s capabilities for tangible health benefits for a variety of applications.

More recently, news surrounding non-steroidal anti-inflammatory drugs, or NSAIDs, has circulated, inciting increased interest in plant-based alternatives. NSAIDs are commonly known to block or impair the initial stage of healing by severely blunting inflammation.2 Conversely, Longvida supplementation, as examined by the researchers in this study, significantly decreased VAS and WOMAC scores when compared to baseline from day 45 onwards, an effect that was comparable to a low dose of ibuprofen (NSAID).1 Longvida did not produce statistically significant changes in any of the inflammatory markers (i.e. PGE2, TNF α, IL6, IL1β and LTB4), which supports findings from previous studies showing that Longvida does not completely block the inflammatory response, rather mediates a healthy inflammatory response, indicating efficacy in subjective pain scores. A low dose of Longvida modulates the inflammation produced by a stressor due to its immunomodulatory effects and promotes a healthy, balanced inflammatory response.1

The key to the success of Longvida lies within the patented and proprietary Solid Lipid Curcumin Particle Technology, or SLCP. Developed by University neuroscientists as an absorption promoting technology, SLCP allows the uptake of free curcumin into the bloodstream and target tissues. As we approach nearly 15 years of commercial availability, we are excited to further delve into the seemingly limitless frontier of tangible health applications and expanding pedigree of science in support of our Optimized Curcumin. With category concerns surrounding adulteration on the rise, it is equally imperative to support an efficacious offering with safety and traceability efforts.

This publication not only expands upon the impressive portfolio of supportive efficacy research, but also further substantiates the safety of this long-standing branded ingredient. The mounting research and support for Longvida Optimized Curcumin truly sets the standard for high-caliber ingredient offerings.

References:

1. Gupte PA et al. J Inflamm Res. 2019. 12: 145-152. doi: 10.2147/JIR.S205390
2. Cleveland Clinic. 2020. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). ­­Retrieved May 2020 from https://my.clevelandclinic.org/health/drugs/11086-non-steroidal-anti-inflammatory-medicines-nsaids